Please	tvna	_	alus	elon	(+)	inside	this	box	_
riease	type	ø	hinz	siyn	(*)	1112106	4113	~	

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of

3	Complete if Known
Application Number	10/075,994
Filing Date	February 15, 2002
First Named Inventor	Kasid et al.
Group Art Unit	1615
Examiner Name	Unassigned
Attorney Docket Number	219604

	U.S. PATENT DOCUMENTS							
			U.S. Patent Document					
Examir Onitial		Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
	2	BE	5,563,255		Monia et al.	Oct. 8, 1996		
		BF	5,656,612		Monia	Aug. 12, 1997		
		BG	5,665,710		Rahman et al.	Sep. 9, 1997		
		вн	5,744,362		Monia et al.	Apr. 28, 1998	_	
		BI	5,919,619		Tullis	July 16, 1999		
		ВJ	5,919,773		Monia et al.	July 6, 1999		
		BK	5,952,229		Monia et al.	Sep. 14, 1999		
		BL	5,981,731		Monia	Nov. 9, 1999		
		ВМ	6,090,626		Monia et al.	July 18, 2000		
		BN	6,096,720		Love et al.	Aug. 1, 2000		
	$\Box$	во	6,114,517		Monia et al.	Sep. 5, 2000		
		BP	6,358,932	B1	Monia	Mar. 19, 2002		
		BQ	6,391,636	B1	Monia	May 21, 2002		
7		BR	6,410,518	B1	Monia	June 25, 2002		

				FORE	IGN PATENT DOCUMENTS			
		F	oreign Patent Docume	nt			Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
Q A	BS	wo	93/04170		The United States of America	Mar. 4, 1993		I
010	вт	wo	93/06248		The United States of America	April 1, 1993		
	ВU	wo	94/15645		Texas Biotechnology Corp.	July 21, 1994		
	BV	wo	94/23755		Board of Regents of the University of Nebraska	Oct. 27, 1994		
	BW	wo	98/18489		The UAB Research Foundation	May 7, 1998		
	вх	wo	99/02167		ISIS Pharmaceuticals, Inc.	Jan. 21, 1999		

	<del></del>	OTHER - NON PATENT LITERATURE DOCUMENTS	-			
Examiner Initials	I I TOOK MAGAZING INUMAL SERIAL SYMPOSIUM CATAING EIC I GATE DAGE(S) VOIUME-ISSUE DUMPER (		Yes	lation No**		
72	BY	et al., Nucl. Acid. Res., 14(2), 1009-15 (1988)				
(1)	BZ	Carroll et al., J. Biol. Chem., 266(23), 14964-69 (1991)				
	CA	Kasid et al., Science, 243, 1354-56 (1989)				
	СВ	Kizaka-Kondoh et al., Mol. Cell. Biol., 12(11), 5078-86 (1992)				
	CC	Kolch et al., Nature, 349(6308), 426-28 (1991)				
	CD	Monia et al., Nature Med., 2(6), 668-75 (1996)				
	CE	Patel et al., Mol. Carcinogen, 8(1), 7-12 (1993)				
	CF	Reidel et al., Eur. J. Immunol., 23, 3146-50 (1993)				
1	CG	Törnkvist et al., J. Biol. Chem., 269, 13919-921 (1994)				

Examiner Signature Date Considered

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box	FATPA

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSUR STATEMENT BY APPLICATION

(Use as many sheets as necessary)

Sheet of

	Complete if Known
Application Number	10/075,994
Filing Date	February 15, 2002
First Named Inventor	Kasid et al.
Group Art Unit	1615
Examiner Name	Unassigned
Attorney Docket Number	219604

			<del></del>	U.S. PATENT DOCUMENTS		
U.S. Patent Document			cument			
Examiner Initials	Doc No:	Application or Parent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
	BE	5,563,255		Monte et al.	Oct. 8, 1996	<u> </u>
	BF.	5,656,6 2	<i>P</i> 1	Moni	Mg_12, 1997	
	BG	5,665,7 0		Ranman et al.	Sep. 99	
	ВН	5,744,362		Monia et al.	Apr. 28, 998	
	ВІ	5,919,019		fullis	July 16, 1999	
	BJ	5,919,73		Monia et al.	July 6, 1999	
-	ВК	5,952,22		Monia et al.	Sep. 14, 1999	
	BL	5,981,731		Monia	Nov. 9, 1999	
	ВМ	6,090,626		Monia et al.	July 18, 2000	
	BN	6,096,720		Love et al.	Aug. 1, 2000	
	ВО	6,114,517		Monia et al.	Sep. 5, 2000	
	BP	6,358,932	B1	Monia	Mar. 19, 2002	
	BQ	6,391,636	B1	Monia 🕴	May 21, 2002	
	BR	6,410,518	B1	Monia 🦸	June 25, 2002	

				FORE	IGN PATENT DOCUMENTS			
		F	oreign Patent Docume	nt	<i>y</i>		Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
	BS	WO	93/04170		The United States of America	Mar. 4, 1993		
	BT	WO	93/06248		The United States of America	April 1, 1993		
	BU	WO	94/15645		Texas Biotechnology Corp.	July 21, 1994		
	BV	wo	94/23755		Board of Regents of the University of Nebraska	Oct. 27, 1994		
	BW	wo	98/18489		The UAB Research Foundation	May 7, 1998	_	†
	вх	WO	99/02167		SIS Pharmaceuticals, Inc.	Jan. 21, 1999		

		OTHER - NON PATENT LITERATURE DOCUMENTS			
Examiner	Doc.	Include name of the author (in CARMAL LETTERS), title of the article (when appropriate), title of the item			
Initials	No.	(book, magazine, journal, serial, symbosium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No**	
	BY	Bonner et al., <i>Nucl. Acid. Res.</i> , 14(2), 1009-15 (1988)			
	ВZ	Carroll et al., J. Biol. Chem., 266(23), 14964-69 (1991)			
	CA	Kasid et al., Science, 248, 1354-56 (1989)			
	CB	Kizaka-Kondoh et al., Mol. Cell. Biol., 12(11), 5078-86 (1992)			
	C	Kolch et al., Nature, 3/49(6308), 426-28 (1991)			
	CD	Monia et al., Nature/Med., 2(6), 668-75 (1996)			
	CE	Patel et al., Mol. @arcinogen, 8(1), 7-12 (1993)			
	CF	Reidel et al., Eug. J. Immunol., 23, 3146-50 (1993)			
	CG	Törnkvist et al. J. Biol. Chem., 269, 13919-921 (1994)			
		1			

Examiner Signature

Date Considered

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

	SEP 1 5 2003 y Substitute for form; 1449A/B/PTO
٦	L. INFORMATION DISCLOSURE

Sheet

TATEMENT BY APPLICANT

of

(Use as many sheets as necessary)

	Complete if Known		
Application Number	10/075,994		32
Filing Date	February 15, 2002	\(\frac{1}{2}\)	6 177
First Named Inventor	Kasid et al.	CZ.	<b>% 9</b>
Group Art Unit	Unassigned	C	7 5
Examiner Name	Unassigned	7	5
Attorney Docket Number	219604		19 B.

OTHER - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Doc. (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, Initials No. city and/or country where published. No\* GOKHALE et al., "Antisense raf oligodeoxyribonucleotide is protected by liposomal AR encapsulation and inhibits Raf-1 protein expression in vitro and in vivo; implication for gene therapy of radioresistant cancer," Gene Therapy, 4, 1289-1299 (1997) AS GOKHALE et al., "Antisense raf Oligodeoxyribonucleotide Is a Radiosensitizer In Vivo." Antisense & Nucleic Acid Drug Development, 9, 191-201 (1999) JAMES, "Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes," Antiviral Chem. & Chemoth., 2. 191-214 (1991) KASID et al., "Effect of Antisense c-raf-1 on Tumorigenicity and Radiation Sensitivity of AU a Human Squamous Carcinoma," Science, 243, 1354-1356 (1989) LAPPALAINEN et al., "Comparison of Cell Proliferation and Toxicity Assays Using Two Cationic Liposomes," *Pharmaceutical Research*, 11(8), 1127-1131 (1994) LITIZINGER et al., "Fate of cationic liposomes and their complex with oligonucleotide in vivo," Biochimica et Biophisica Acta, 1281, 139-149 (1996) MAHER et al., "Specific Hybridization Arrest of Dihydrofolate Reductase mRNA in Vitro AXUsing Anti-sense RNA or Anti-sense Oligonucleotides," Archives of Biochemistry and Biophysics, 253, 214-220 (1987) MILNER et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," Nature Biotechnology, 15, 537-541 (1997) PATEL et al., "Nucleotide Sequence Analysis of c-raf-1 cDNA and Promoter From a ΑZ Radiation-Resistant Human Squamous Carcinoma Cell Line: Deletion Within Exon 17," Molecular Carcinogenesis, 8, 7-12 (1993) BA SCHOFIELD et al., "Non-viral approaches to gene therapy," Brit. Med. Bull., 51, 56-71 (1995)SEUNG et al., "Genetic Radiotherapy Overcomes Tumor Resistance to Cytotoxic BB Agent," Cancer Research, 55, 5561-5565 (1995) SOLDAATENKOV et al., "Inhibition of Raf-1 Protein Kinase by Antisense Phosphorothioate Oligodeoxyribonucleotide Is Associated with Sensitization of Human Laryngeal Squamous Carcinoma Cells to Gamma Radiation," Cancer J. Sci. Am., 3, 13-20 (1997) VERMA et al., "Gene therapy - promises, problems and prospects," Nature, 389, 239-

	$\triangle$					_	
Examiner Signature	1	2 -	Date Considered	-7/	7/	04	

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

ol P	us sign ( ) inside this bo	»× → [-	E			
E VI	2000 - 63		•		Complete if Known	₹ <b>7</b>
Substitute for form 1449A/B/PTO				Application Number	10/075,994	4
A THURST	MATION	חופר	OSHDE	Filing Date	February 15, 2002	% CA
ฟิศิติศ์MATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Kasid et al.	
				Group Art Unit	1615	1, 6, 1
	(Use as many she	ets as ned	cessary)	Examiner Name	Unassigned	73 By
Sheet	1	of	2	Attorney Docket Number	219604	160

				U.S. PATENT DOCUMENTS		300
		U.S. Patent Do	cument			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
$\sqrt{2}$	AA	5,283,185		Epand et al.	Feb. 1, 1994	
-U, $X$	AB	5,641,662		Debs et al.	June 24, 1997	»·····
	AC	5,696,277	1.	Hostetler et al.	Dec. 9, 1997	
	ΑD	5,756,122		Thierry et al.	May 26, 1998	1
	ΑE	5,827,703		Debs et al.	Oct. 27, 1998	)
1 .	AF	5,952,229		Monia et al.	Sep. 14, 1999	
	AG	6,120,798		Allen et al.	Sep. 19, 2000	
	AH	6,126,965		Kasid et al.	Oct. 3, 2000	
	ΑI	6,248,351	B1	Xing et al.	June 19, 2001	
V	AJ	6,333,314	B1	Kasid et al.	Dec. 25, 2001	<u></u>
			<u> </u>			
			<u> </u>			

FOREIGN PATENT DOCUMENTS										
		F	oreign Patent Docume	nt		Translation				
Examiner Initials	Doc. No.			Name of Patentee or Applicant	Date of Publication	Yes	No*+			
	,AK	WO	95/11670		THE LIPOSOME COMPANY, INC.	May 4, 1995				
V Z	AL	wo	95/32987	1	MACEUTICALS, INC.	Dec. 7, 1995				
777										
	-									
								i		
							i	·		
								1		

		OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Doc.	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item				
Initials No.		(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.				
172	АМ	BRANCH, "A Good Antisense Molecule is Hard to Find," TIBS, 23, 45-50 (1998)				
Did	AN	CROOKE, "Antisense Research and Application," Springer-Verlag, 1, 1-50 (1998)				
	ΑO	CRYSTAL, "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," Science, 270, 404-410 (1995)				
	ΑP	FRIEDMANN, "Overcoming the Obstacles to Gene Therapy," Science America, June, 96-101 (1997)				
1	AQ	GOKHALE et al., "Enhanced inhibition of Raf-1 kinase by liposomal antisense raf oligodeoxyribonucleotide in human squamous carcinoma cells," American Asso. Cancer Research, 37, Poster Section 6 #2807 (1996)				

	-					/	<i>;</i>	
Examiner Signature		1		Date Considered	7-1	71	OY	

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).